🔴 GRAIL is trading 10% down today after Q3 revenue fell short of expectations

GRAIL is trading at $128.96 (-10.24%) after November 4 results showed Q3 revenue of $37.5 million, below analyst expectations.

• Galleri test volume rose 24% to more than 56,000, but growth did not prevent the revenue shortfall.
• Management lowered full-year Galleri sales revenue growth outlook to 17%–21%; promotional pricing weighed on average selling prices and margins. The FDA decision is expected in early Q1 2027.